Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study

Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular &amp; Electrodiagnostic Medicine Annual Meeting.

Medicine

Health & Fitness

Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.

Share Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study

Sign up to save your podcasts

Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study

Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study